Combo patent granted | AMRN Message Board Posts


Amarin Corporation plc

  AMRN website

AMRN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  9139 of 9205  at  1/26/2023 1:09:23 AM  by

lettruthringout


Combo patent granted

  • Patent number: 11547710
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and a statin and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: January 10, 2023
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: George Grandolfi
     
     
    SUMMARY

     

    In one embodiment, the invention provides a pharmaceutical composition comprising a fatty acid component (e.g., ethyl eicosapentaenoate) and a statin (e.g., atorvastatin, rosuvastatin or simvastatin). In one embodiment, the fatty acid component and the statin are present in a same dosage unit. In another embodiment, the fatty acid component is present in a capsule and the statin is present on an exterior surface of the capsule wall. In some embodiments, the statin is sprayed, coated or layered on to an exterior surface of the capsule shell.

     

    In another embodiment, the invention provides a pharmaceutical composition comprising fatty acid component encapsulated in a capsule shell and a statin dispersed in the fatty acid component. In one embodiment the statin is formed into a solid dosage unit such as a capsule that is dispersed in the fatty acid component. In some embodiments, the solid dosage unit comprising the statin is selected such that it does not substantially disintegrate or dissolve inside the capsule until after oral administration to a subject.

     

    In any embodiment disclosed herein, the fatty acid component may comprise at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 96%, by weight of all fatty acids present, EPA or derivative thereof such as ethyl eicosapentaenoate. In any embodiment disclosed herein, the pharmaceutical composition can include not more than about 10%, not more than about 4%, not more than about 5% or substantially no DHA or esters thereof, by weight of all fatty acids present.

     

    In still other embodiments, the present invention provides methods of treating or preventing a cardiovascular-related disease using compositions as described herein.
     


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 4  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
9140 Re: Combo patent granted liposghost 0 1/26/2023 4:12:10 PM




Financial Market Data provided by
.
Loading...